Strategies to overcome the side effects of chimeric antigen receptor T cell therapy

Mohadeseh Mirzaee Godarzee ◽  
Bashdar Mahmud Hussen ◽  
Ehsan Razmara ◽  
Benyamin Hakak‐Zargar ◽  
Fatemeh Mohajerani ◽  
Immunotherapy ◽  
2020 ◽  
Vol 12 (18) ◽  
pp. 1341-1357
Nashwa El-Khazragy ◽  
Sherief Ghozy ◽  
Passant Emad ◽  
Mariam Mourad ◽  
Diaaeldeen Razza ◽  

Taking advantage of the cellular immune system is the mainstay of the adoptive cell therapy, to induce recognition and destruction of cancer cells. The impressive demonstration of this principle is chimeric antigen receptor-modified T (CAR-T)-cell therapy, which had a major impact on treating relapsed and refractory hematological malignancies. Despite the great results of the CAR-T-cell therapy, many tumors are still able to avoid immune detection and further elimination, as well as the possible associated adverse events. Herein, we highlighted the recent advances in CAR-T-cell therapy, discussing their applications beneficial functions and side effects in hematological malignancies, illustrating the underlying challenges and opportunities. Furthermore, we provide an overview to overcome different obstacles using potential manufacture and treatment strategies.

Javad Masoumi ◽  
Abdollah Jafarzadeh ◽  
Jalal Abdolalizadeh ◽  
Haroon Khan ◽  
Jeandet Philippe ◽  

2021 ◽  
Vol 27 (3) ◽  
pp. S355
Nishi Shah ◽  
Ana Alarcon ◽  
Meighan Palazzo ◽  
Josel D. Ruiz ◽  
Connie W Batlevi ◽  

2021 ◽  
Vol 7 (2) ◽  
pp. 156
Will Garner ◽  
Palash Samanta ◽  
Ghady Haidar

Studies describing invasive fungal infections (IFIs) after chimeric antigen receptor-modified T-cell (CAR-T-cell) therapy are limited. Although post-CAR-T-cell IFIs appear to be uncommon, they are associated with significant morbidity and mortality. Specific risk factors for IFIs in CAR-T-cell recipients have not been fully characterized and are often extrapolated from variables contributing to IFIs in patients with other hematologic malignancies or those undergoing hematopoietic cell transplant. Optimal prophylaxis strategies, including the use of yeast versus mold-active azoles, also remain ill-defined. Further research should investigate key risk factors for IFIs and establish an evidence-based approach to antifungal prophylaxis in these patients in order to improve clinical outcomes.

2021 ◽  
Vol 27 (3) ◽  
pp. S211-S212
Eddie Stephens ◽  
Ansh Mehta ◽  
Tanya Persoon ◽  
Shannon Baker ◽  
Remy David ◽  

Eric A. Apaydin ◽  
Andrea S. Richardson ◽  
Sangita Baxi ◽  
Jerry Vockley ◽  
Olamigoke Akinniranye ◽  

Sign in / Sign up

Export Citation Format

Share Document